{"id":"lyophilized-albiglutide-dcc-pen-injector","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By activating the GLP-1 receptor, albiglutide increases insulin secretion in response to high blood glucose levels, decreases glucagon secretion, and slows gastric emptying, leading to improved glycemic control.","oneSentence":"Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:56.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT02683746","phase":"PHASE3","title":"Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-16","conditions":"Diabetes Mellitus, Type 2","enrollment":308},{"nctId":"NCT03015519","phase":"PHASE3","title":"A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2017-08-14","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT02660736","phase":"PHASE1","title":"Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02","conditions":"Diabetes Mellitus, Type 2","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lyophilized albiglutide DCC pen injector","genericName":"Lyophilized albiglutide DCC pen injector","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to lower blood glucose levels. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}